Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3’,5’-bisphosphate as a potent enzyme inhibitor

G.J. Lockbaum(Accent Therapeutics (United States)), P. Ann Boriack‐Sjodin(Accent Therapeutics (United States))
Communications Biology
April 9, 2025
Cited by 1


Related Papers